These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 15460194)

  • 1. Visceral leishmaniasis (kala-azar) and pregnancy.
    Figueiró-Filho EA; Duarte G; El-Beitune P; Quintana SM; Maia TL
    Infect Dis Obstet Gynecol; 2004; 12(1):31-40. PubMed ID: 15460194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of kala-azar during pregnancy.
    Thakur CP; Sinha GP; Sharma V; Barat D
    Natl Med J India; 1993; 6(6):263-5. PubMed ID: 7950931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
    J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of visceral leishmaniasis in India.
    Bora D
    Natl Med J India; 1999; 12(2):62-8. PubMed ID: 10416321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis and pregnancy: analysis of cases reported in a central-western region of Brazil.
    Figueiró-Filho EA; El Beitune P; Queiroz GT; Somensi RS; Morais NO; Dorval ME; Quintana SM; Duarte G
    Arch Gynecol Obstet; 2008 Jul; 278(1):13-6. PubMed ID: 18087708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 11. A new strategy for elimination of kala-azar from rural Bihar.
    Thakur CP
    Indian J Med Res; 2007 Nov; 126(5):447-51. PubMed ID: 18160749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.
    Thakur CP; Ahmed S
    Indian J Med Res; 2001 Jan; 113():14-8. PubMed ID: 11280166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Visceral leishmaniases].
    Rosenthal E; Marty P
    Rev Prat; 2004 Dec; 54(20):2211-6. PubMed ID: 15736529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of visceral leishmaniasis in 2004.
    Murray HW
    Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.